Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MI5G
|
|||
| Former ID |
DIB007717
|
|||
| Drug Name |
RG2077
|
|||
| Indication | Graft-versus-host disease [ICD-11: 4B24; ICD-9: 279.5] | Phase 1/2 | [1] | |
| Company |
Repligen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00094380) Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.